|
2023-08-01 |
2023-08-01 |
S
Sale
|
King Andrew James
Chief Scientific Officer
Officer
|
1,168
-5.7%
39.03
45,586
USD
|
1,168
-5.7%
|
39.03
|
45,586
USD
|
|
|
2023-05-31 |
2023-05-30 |
PS
Planned sale
|
Greenman William Mariner
Non-Executive Director
|
1,155
-4.7%
23.30
26,912
USD
|
1,155
-4.7%
|
23.30
|
26,912
USD
|
|
|
2023-04-26 |
2023-04-24 |
PS
Planned sale
|
DOBMEIER ERIC
President, CEO
Executive Director
|
23,800
-7.3%
21.58
513,528
USD
|
23,800
-7.3%
|
21.58
|
513,528
USD
|
|
|
2023-04-19 |
2023-04-17 |
S
Sale
|
Jerel Davis
Non-Executive Director
|
295,808
-40.0%
20.75
6,138,223
USD
|
295,808
-40.0%
|
20.75
|
6,138,223
USD
|
|
|
2023-04-04 |
2023-04-04 |
PS
Planned sale
|
Krishnan Mahesh
Non-Executive Director
|
924
-42.0%
23.01
21,261
USD
|
924
-42.0%
|
23.01
|
21,261
USD
|
|
|
2023-04-05 |
2023-04-03 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
5,000
-22.7%
23.34
116,718
USD
|
5,000
-22.7%
|
23.34
|
116,718
USD
|
|
|
2023-03-03 |
2023-03-01 |
S
Sale
|
Jerel Davis
Non-Executive Director
|
36,751
-14.8%
22.75
836,085
USD
|
36,751
-14.8%
|
22.75
|
836,085
USD
|
|
|
2023-03-03 |
2023-03-01 |
S
Sale
|
Jerel Davis
Non-Executive Director
|
123,249
-14.6%
22.75
2,803,915
USD
|
123,249
-14.6%
|
22.75
|
2,803,915
USD
|
|
|
2023-03-03 |
2023-03-01 |
S
Sale
|
Jerel Davis
Non-Executive Director
|
240,000
-10.2%
22.75
5,460,000
USD
|
240,000
-10.2%
|
22.75
|
5,460,000
USD
|
|
|
2023-02-15 |
2023-02-10 |
S
Sale
|
King Andrew James
Chief Scientific Officer
Officer
|
2,392
-10.9%
23.75
56,806
USD
|
2,392
-10.9%
|
23.75
|
56,806
USD
|
|
|
2023-02-15 |
2023-02-10 |
S
Sale
|
BJERKHOLT ERIC
Chief Financial Officer
Officer
|
857
-2.2%
23.75
20,352
USD
|
857
-2.2%
|
23.75
|
20,352
USD
|
|
|
2023-02-15 |
2023-02-10 |
S
Sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
3,700
-2.4%
23.75
87,869
USD
|
3,700
-2.4%
|
23.75
|
87,869
USD
|
|
|
2023-02-15 |
2023-02-10 |
S
Sale
|
DOBMEIER ERIC
President, CEO
Executive Director
|
8,097
-2.6%
23.75
192,292
USD
|
8,097
-2.6%
|
23.75
|
192,292
USD
|
|
|
2023-02-02 |
2023-01-31 |
S
Sale
|
King Andrew James
Chief Scientific Officer
Officer
|
3,244
-17.7%
24.68
80,069
USD
|
3,244
-17.7%
|
24.68
|
80,069
USD
|
|
|
2023-02-02 |
2023-01-31 |
S
Sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
4,566
-3.0%
24.68
112,700
USD
|
4,566
-3.0%
|
24.68
|
112,700
USD
|
|
|
2023-02-02 |
2023-01-31 |
S
Sale
|
BJERKHOLT ERIC
Chief Financial Officer
Officer
|
2,891
-7.2%
24.68
71,357
USD
|
2,891
-7.2%
|
24.68
|
71,357
USD
|
|
|
2023-02-01 |
2023-01-31 |
S
Sale
|
DOBMEIER ERIC
President, CEO
Executive Director
|
7,688
-2.6%
24.68
189,757
USD
|
7,688
-2.6%
|
24.68
|
189,757
USD
|
|
|
2023-02-01 |
2023-01-30 |
PS
Planned sale
|
DOBMEIER ERIC
President, CEO
Executive Director
|
25,000
-8.4%
24.54
613,613
USD
|
25,000
-8.4%
|
24.54
|
613,613
USD
|
|
|
2023-01-04 |
2023-01-03 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
10,000
-50.0%
25.82
258,183
USD
|
10,000
-50.0%
|
25.82
|
258,183
USD
|
|
|
2022-12-15 |
2022-12-13 |
PS
Planned sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
10,000
-6.5%
25.00
250,005
USD
|
10,000
-6.5%
|
25.00
|
250,005
USD
|
|
|
2022-12-02 |
2022-12-01 |
PS
Planned sale
|
DOBMEIER ERIC
President, CEO
Executive Director
|
30,000
-11.0%
22.31
669,351
USD
|
30,000
-11.0%
|
22.31
|
669,351
USD
|
|
|
2022-12-02 |
2022-12-01 |
S
Sale
|
BJERKHOLT ERIC
Chief Financial Officer
Officer
|
5,770
-14.9%
22.29
128,602
USD
|
5,770
-14.9%
|
22.29
|
128,602
USD
|
|
|
2022-11-09 |
2022-11-07 |
PS
Planned sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
10,000
-6.5%
22.16
221,642
USD
|
10,000
-6.5%
|
22.16
|
221,642
USD
|
|
|
2022-10-11 |
2022-10-06 |
S
Sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
7,360
-4.9%
19.69
144,933
USD
|
7,360
-4.9%
|
19.69
|
144,933
USD
|
|
|
2022-10-11 |
2022-10-06 |
S
Sale
|
King Andrew James
Chief Scientific Officer
Officer
|
3,557
-22.2%
19.69
70,044
USD
|
3,557
-22.2%
|
19.69
|
70,044
USD
|
|
|
2022-09-06 |
2022-09-02 |
B
Purchase
|
Thomas Dolca
Non-Executive Director
|
300
+3.1%
21.20
6,360
USD
|
300
+3.1%
|
21.20
|
6,360
USD
|
|
|
2022-09-06 |
2022-09-02 |
B
Purchase
|
Thomas Dolca
Non-Executive Director
|
9,700
+inf%
21.22
205,834
USD
|
9,700
+inf%
|
21.22
|
205,834
USD
|
|
|
2022-08-05 |
2022-08-04 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
5,000
-45.9%
20.00
100,000
USD
|
5,000
-45.9%
|
20.00
|
100,000
USD
|
|
|
2022-07-13 |
2022-07-11 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
5,000
-45.9%
18.09
90,468
USD
|
5,000
-45.9%
|
18.09
|
90,468
USD
|
|
|
2022-06-01 |
2022-05-27 |
B
Purchase
|
AKKARAJU SRINIVAS
Non-Executive Director
|
570,000
+12.4%
14.00
7,980,000
USD
|
570,000
+12.4%
|
14.00
|
7,980,000
USD
|
|
|
2022-05-27 |
2022-05-25 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
5,000
+2.5%
13.03
65,148
USD
|
5,000
+2.5%
|
13.03
|
65,148
USD
|
|
|
2022-04-13 |
2022-04-11 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
5,000
-45.9%
15.36
76,812
USD
|
5,000
-45.9%
|
15.36
|
76,812
USD
|
|
|
2022-02-23 |
2022-02-18 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
2,500
-29.8%
13.00
32,500
USD
|
2,500
-29.8%
|
13.00
|
32,500
USD
|
|
|
2022-02-14 |
2022-02-11 |
S
Sale
|
BJERKHOLT ERIC
Chief Financial Officer
Officer
|
895
-3.9%
12.74
11,403
USD
|
895
-3.9%
|
12.74
|
11,403
USD
|
|
|
2022-02-14 |
2022-02-11 |
S
Sale
|
Glicklich Alan
Chief Medical Officer
Officer
|
2,391
-23.3%
12.74
30,464
USD
|
2,391
-23.3%
|
12.74
|
30,464
USD
|
|
|
2022-02-14 |
2022-02-11 |
S
Sale
|
King Andrew James
Chief Scientific Officer
Officer
|
2,498
-22.9%
12.74
31,827
USD
|
2,498
-22.9%
|
12.74
|
31,827
USD
|
|
|
2022-02-14 |
2022-02-11 |
S
Sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
3,735
-2.6%
12.74
47,587
USD
|
3,735
-2.6%
|
12.74
|
47,587
USD
|
|
|
2022-02-11 |
2022-02-10 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
2,500
-37.9%
13.31
33,275
USD
|
2,500
-37.9%
|
13.31
|
33,275
USD
|
|
|
2022-01-05 |
2022-01-03 |
PS
Planned sale
|
Versant Venture Capital VII, L.P.
Large shareholder
|
92,000
-14.3%
16.00
1,472,018
USD
|
92,000
-14.3%
|
16.00
|
1,472,018
USD
|
|
|
2022-01-05 |
2022-01-03 |
PS
Planned sale
|
Versant Venture Capital VII, L.P.
Large shareholder
|
308,000
-14.2%
16.00
4,928,062
USD
|
308,000
-14.2%
|
16.00
|
4,928,062
USD
|
|
|
2022-01-05 |
2022-01-03 |
PS
Planned sale
|
Versant Venture Capital VII, L.P.
Large shareholder
|
600,000
-14.2%
16.00
9,600,120
USD
|
600,000
-14.2%
|
16.00
|
9,600,120
USD
|
|
|
2022-01-05 |
2022-01-03 |
PS
Planned sale
|
Jerel Davis
Non-Executive Director
Large shareholder
|
92,000
-14.3%
16.00
1,472,018
USD
|
92,000
-14.3%
|
16.00
|
1,472,018
USD
|
|
|
2022-01-05 |
2022-01-03 |
PS
Planned sale
|
Jerel Davis
Non-Executive Director
Large shareholder
|
308,000
-14.2%
16.00
4,928,062
USD
|
308,000
-14.2%
|
16.00
|
4,928,062
USD
|
|
|
2022-01-05 |
2022-01-03 |
PS
Planned sale
|
Jerel Davis
Non-Executive Director
Large shareholder
|
600,000
-14.2%
16.00
9,600,120
USD
|
600,000
-14.2%
|
16.00
|
9,600,120
USD
|
|
|
2021-11-17 |
2021-11-15 |
B
Purchase
|
AKKARAJU SRINIVAS
Non-Executive Director
|
1,215,000
+36.0%
14.00
17,010,000
USD
|
1,215,000
+36.0%
|
14.00
|
17,010,000
USD
|
|
|
2021-11-12 |
2021-11-10 |
PS
Planned sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
6,230
-4.4%
15.48
96,440
USD
|
6,230
-4.4%
|
15.48
|
96,440
USD
|
|
|
2021-11-12 |
2021-11-09 |
PS
Planned sale
|
King Andrew James
Chief Scientific Officer
Officer
|
5,000
-55.0%
13.53
67,660
USD
|
5,000
-55.0%
|
13.53
|
67,660
USD
|
|
|
2021-11-09 |
2021-11-08 |
PS
Planned sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
13,770
-8.9%
15.17
208,938
USD
|
13,770
-8.9%
|
15.17
|
208,938
USD
|
|
|
2021-11-09 |
2021-11-05 |
PS
Planned sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
5,000
-3.1%
14.00
70,000
USD
|
5,000
-3.1%
|
14.00
|
70,000
USD
|
|
|
2021-11-09 |
2021-11-05 |
PS
Planned sale
|
Frohlich Tom
Chief Operating Officer
Officer
|
15,000
-8.6%
14.00
210,000
USD
|
15,000
-8.6%
|
14.00
|
210,000
USD
|
|
|
2021-06-17 |
2021-06-16 |
PS
Planned sale
|
Glicklich Alan
Chief Medical Officer
Officer
|
20,000
-100.0%
16.35
326,968
USD
|
20,000
-100.0%
|
16.35
|
326,968
USD
|
|
|
2021-05-18 |
2021-05-14 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
1,000
+1.3%
14.44
14,440
USD
|
1,000
+1.3%
|
14.44
|
14,440
USD
|
|
|
2020-12-10 |
2020-12-09 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
2,000
+3.6%
13.08
26,150
USD
|
2,000
+3.6%
|
13.08
|
26,150
USD
|
|
|
2020-12-10 |
2020-12-08 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
2,000
+3.8%
13.24
26,483
USD
|
2,000
+3.8%
|
13.24
|
26,483
USD
|
|
|
2020-11-23 |
2020-11-23 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
929
+1.8%
13.67
12,699
USD
|
929
+1.8%
|
13.67
|
12,699
USD
|
|
|
2020-11-23 |
2020-11-20 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
571
+1.1%
13.69
7,817
USD
|
571
+1.1%
|
13.69
|
7,817
USD
|
|
|
2020-11-23 |
2020-11-19 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
500
+1.0%
13.50
6,750
USD
|
500
+1.0%
|
13.50
|
6,750
USD
|
|
|
2020-11-13 |
2020-11-11 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
2,500
+5.2%
13.75
34,375
USD
|
2,500
+5.2%
|
13.75
|
34,375
USD
|
|
|
2020-11-13 |
2020-11-10 |
B
Purchase
|
DOBMEIER ERIC
President, CEO
Executive Director
|
2,000
+4.3%
13.86
27,720
USD
|
2,000
+4.3%
|
13.86
|
27,720
USD
|
|
|
2020-09-17 |
2020-09-15 |
S
Sale
|
Ferber Celeste
SVP, GC and Secretary
Officer
|
2,396
-5.8%
2.39
5,731
USD
|
2,396
-5.8%
|
2.39
|
5,731
USD
|
|
|
2020-09-17 |
2020-09-15 |
S
Sale
|
Templeman Blaine
Chief Legal Officer
Officer
|
12,369
-9.2%
2.39
29,585
USD
|
12,369
-9.2%
|
2.39
|
29,585
USD
|
|
|
2020-09-17 |
2020-09-15 |
S
Sale
|
ISAACS STEPHEN T
President and CEO
Executive Director
|
32,481
-10.4%
2.39
77,691
USD
|
32,481
-10.4%
|
2.39
|
77,691
USD
|
|
|
2020-08-11 |
2020-08-07 |
S
Sale
|
Nuyten Dimitry SA
Chief Medical Officer
Officer
|
3,538
-29.5%
2.55
9,036
USD
|
3,538
-29.5%
|
2.55
|
9,036
USD
|
|
|
2020-08-11 |
2020-08-07 |
S
Sale
|
Ferber Celeste
SVP, GC and Secretary
Officer
|
7,951
-16.2%
2.55
20,308
USD
|
7,951
-16.2%
|
2.55
|
20,308
USD
|
|
|
2020-08-11 |
2020-08-07 |
S
Sale
|
Templeman Blaine
Chief Legal Officer
Officer
|
7,951
-5.6%
2.55
20,308
USD
|
7,951
-5.6%
|
2.55
|
20,308
USD
|
|
|
2020-02-26 |
2020-02-25 |
S
Sale
|
van Elsas Andrea
Chief Scientific Officer
Officer
|
6,823
-1.5%
3.51
23,954
USD
|
6,823
-1.5%
|
3.51
|
23,954
USD
|
|
|
2020-01-06 |
2020-01-03 |
S
Sale
|
van Elsas Andrea
Chief Scientific Officer
|
73,311
-14.1%
1.19
87,108
USD
|
73,311
-14.1%
|
1.19
|
87,108
USD
|
|
|
2019-12-16 |
2019-12-12 |
S
Sale
|
Ferber Celeste
SVP, GC and Secretary
Officer
|
408
-1.5%
1.16
475
USD
|
408
-1.5%
|
1.16
|
475
USD
|
|
|
2019-12-16 |
2019-12-12 |
S
Sale
|
van Elsas Andrea
Chief Scientific Officer
Officer
|
2,192
-0.4%
1.16
2,550
USD
|
2,192
-0.4%
|
1.16
|
2,550
USD
|
|
|
2019-12-16 |
2019-12-12 |
S
Sale
|
ISAACS STEPHEN T
President and CEO
Executive Director
|
5,897
-2.0%
1.16
6,860
USD
|
5,897
-2.0%
|
1.16
|
6,860
USD
|
|
|
2019-12-16 |
2019-12-12 |
PS
Planned sale
|
Templeman Blaine
Chief Legal Officer
Officer
|
1,264
-1.1%
1.16
1,470
USD
|
1,264
-1.1%
|
1.16
|
1,470
USD
|
|
|
2019-09-17 |
2019-09-13 |
S
Sale
|
van Elsas Andrea
Chief Scientific Officer
|
634
-0.1%
1.31
828
USD
|
634
-0.1%
|
1.31
|
828
USD
|
|
|
2019-09-17 |
2019-09-13 |
S
Sale
|
van Elsas Andrea
Chief Scientific Officer
|
17,959
-3.3%
1.31
23,451
USD
|
17,959
-3.3%
|
1.31
|
23,451
USD
|
|
|
2019-09-17 |
2019-09-13 |
S
Sale
|
Ferber Celeste
SVP, GC and Secretary
|
1,102
-3.9%
1.31
1,439
USD
|
1,102
-3.9%
|
1.31
|
1,439
USD
|
|
|
2019-09-17 |
2019-09-13 |
S
Sale
|
Ferber Celeste
SVP, GC and Secretary
|
1,392
-4.7%
1.31
1,818
USD
|
1,392
-4.7%
|
1.31
|
1,818
USD
|
|
